The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Bimekizumab maintenance therapy for patients with moderate-to-severe plaque psoriasis: 4-year results from BE BRIGHT
|
An analysis of data pooled from the 52-week phase III BE VIVID trial (NCT03370133), the 56-week phase III BE SURE (NCT03412747) and BE READY (NCT03410992) trials, and their OLE BE BRIGHT (NCT03598790) assessed the maintenance of response in 771 patients with moderate-to-severe plaque psoriasis treated with bimekizumab through 4 years.1 Patients received bimekizumab 320 mg Q4W until Week 16, then either Q4W or Q8W until OLE entry and during the OLE. Results from this analysis were presented at the EADV Congress 2024 by Gordon.1 |
| Key learnings |
| At Year 1, 90.7% of patients had a PASI 90 response; 96.5%, 93.7%, and 87.9% of patients maintained their responses at Years 2, 3, and 4, respectively. |
| At Year 1, 75.6% of patients were PASI 100 responders; at Years 2, 3, and 4, 87.3%, 80.9%, and 74.3% of patients, respectively, continued to respond. |
| An IGA 0/1 response was achieved by 88.8% of patients at Year 1, and 96.4%, 93.3%, and 89.5% of patients maintained their responses at Years 2, 3, and 4, respectively. |
| At Year 1, 80.5% of patients were DLQI 0/1 responders, and the responses were maintained by 92.4%, 88.3%, and 82.9% of patients at Years 2, 3, and 4, respectively. |
| These findings demonstrate the benefit of bimekizumab maintenance therapy in patients who responded to treatment after 1 year, with a high proportion of patients maintaining these responses through 4 years. |
Abbreviations: DLQI, Dermatology Life Quality Index; EADV, European Academy of Dermatology and Venereology; IGA, Investigators Global Assessment; OLE, open-label extension; PASI, Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
